Novo Nordisk’s Wegovy Wins US Approval as Heart Treatment (2)

Novo Nordisk A/S’s blockbuster drug Wegovy gained expanded US approval to include reducing the risk for heart attacks and strokes, a move that could further widen use and insurer coverage of the popular anti-obesity medication.

This is the first time a weight-loss therapy has also been approved to help prevent life-threatening cardiovascular events, the Food and Drug Administration said Friday in a statement. The expansion helps cement the idea that Wegovy has real, tangible health benefits beyond cosmetic weight loss.

Novo Nordisk and rival drugmaker Eli Lilly & Co. are racing to study new weight-loss drugs called GLP-1s ...